{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:04:43Z","timestamp":1763535883914},"reference-count":21,"publisher":"Medical Association of Nippon Medical School","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2022,6,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-303","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T22:08:29Z","timestamp":1631570909000},"page":"287-294","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1272","volume":"89","author":[{"given":"Naoko","family":"Shimoda","sequence":"first","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Hirama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinao","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int [Internet]. 2015 Jul;88 (1):17-27. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25786098","DOI":"10.1038\/ki.2015.59"},{"key":"2","unstructured":"2. Nanchisei jinshogai ni kansuru kenkyu chosahan, editor. Ebidensu ni motozuku tahatsuseinouhoujin shinryo gaidorain 2020 [Evidence-Based Clinical Practice Guidelines for Polycystic Kidney Disease 2020]: Tokyo Igaku-sha; 2020. Japanese."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med [Internet]. 2012 Dec 20;367 (25):2407-18. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23121377","DOI":"10.1056\/NEJMoa1205511"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chebib FT, Perrone RD, Chapman AB, et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol [Internet]. 2018 Oct;29 (10):2458-70. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30228150","DOI":"10.1681\/ASN.2018060590"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int [Internet]. 2004 Sep;66 (3):964-73. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15327388","DOI":"10.1111\/j.1523-1755.2004.00843.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hanaoka K, Qian F, Boletta A, et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature [Internet]. 2000 Dec 21-28;408 (6815):990-4. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11140688","DOI":"10.1038\/35050128"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zittema D, van den Berg E, Meijer E, et al. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol [Internet]. 2014 Sep 5;9 (9):1553-62. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24993447","DOI":"10.2215\/CJN.08690813"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med [Internet]. 2017 Nov 16;377 (20):1930-42. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29105594","DOI":"10.1056\/NEJMoa1710030"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Breau RH, Clark E, Bruner B, et al. A simple method to estimate renal volume from computed tomography. Can Urol Assoc J [Internet]. 2013 May-Jun;7 (5-6):189-92. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23826046","DOI":"10.5489\/cuaj.1338"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol [Internet]. 2015 Jan;26 (1):160-72. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24904092","DOI":"10.1681\/ASN.2013101138"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol [Internet]. 2013 Dec;17 (6):834-8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23483323","DOI":"10.1007\/s10157-013-0788-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Katsumata M, Hirawa N, Sumida K, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol [Internet]. 2017 Oct;21 (5):858-65. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28190113","DOI":"10.1007\/s10157-016-1379-0"},{"key":"13","unstructured":"13. Mori T, Oba I, Koizumi K, et al. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial [Internet]. 2013;29:33-7. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24344488"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sen J, Chung E, McGill D. Tolvaptan for heart failure in chronic kidney disease patients: A systematic review and meta-analysis. Heart Lung Circ [Internet]. 2018 Aug;27 (8):928-39. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29602756","DOI":"10.1016\/j.hlc.2017.12.013"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Edwards ME, Chebib FT, Irazabal MV, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol [Internet]. 2018 Aug 7;13 (8):1153-61. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30026287","DOI":"10.2215\/CJN.01520218"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Torres VE, Chapman AB, Devuyst O, et al.  Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant [Internet]. 2018 Mar 1;33 (3):477-89. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28379536","DOI":"10.1093\/ndt\/gfx043"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Torres VE, Higashihara E, Devuyst O, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol [Internet]. 2016 May 6;11 (5):803-11. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26912543","DOI":"10.2215\/CJN.06300615"},{"key":"18","unstructured":"18. Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs [Internet]. 2004 Sep;5 (9):977-83. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15503654"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med [Internet]. 2006 Nov 16;355 (20):2099-112. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17105757","DOI":"10.1056\/NEJMoa065181"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol [Internet]. 2006 Apr 1;97 (7):1064-7. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16563917","DOI":"10.1016\/j.amjcard.2005.10.050"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol [Internet]. 2010 Apr;21 (4):705-12. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20185637","DOI":"10.1681\/ASN.2009080857"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/3\/89_JNMS.2022_89-303\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:33:44Z","timestamp":1656736424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/3\/89_JNMS.2022_89-303\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-303","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"article-number":"JNMS.2022_89-303"}}